Lifeboat Foundation

Johns Hopkins Medicine scientists who arranged for 48 human bioengineered heart tissue samples to spend 30 days at the International Space Station report evidence that the low gravity conditions in space weakened the tissues and disrupted their normal rhythmic beats when compared to Earth-bound samples from the same source.

The scientists said the heart tissues “really don’t fare well in space,” and over time, the tissues aboard the space station beat about half as strongly as tissues from the same source kept on Earth.

The findings, they say, expand scientists’ knowledge of low gravity’s potential effects on astronauts’ survival and health during long space missions, and they may serve as models for studying heart muscle aging and therapeutics on Earth.

The interlocking bricks, which can be repurposed many times over, can withstand similar pressures as their concrete counterparts. Engineers developed a new kind of reconfigurable masonry made from 3D-printed, recycled glass. The bricks could be reused many times over in building facades and internal walls.

What if construction materials could be put together and taken apart as easily as LEGO bricks? Such reconfigurable masonry would be disassembled at the end of a building’s lifetime and reassembled into a new structure, in a sustainable cycle that could supply generations of buildings using the same physical building blocks.

That’s the idea behind circular construction, which aims to reuse and repurpose a building’s materials whenever possible, to minimize the manufacturing of new materials and reduce the construction industry’s “embodied carbon,” which refers to the greenhouse gas emissions associated with every process throughout a building’s construction, from manufacturing to demolition.

Researchers have long observed that a common family of environmental bacteria, Comamonadacae, grow on plastics littered throughout urban rivers and wastewater systems.

Finding could lead to bioengineering solutions to clean up plastic waste.

A new study finds that a common bacterium can break down plastic for food, opening new possibilities for bacteria-based engineering solutions to help clean up plastic waste. Illustration credit Ludmilla Aristilde/Northwestern University.

Continue reading “Wastewater bacteria can break down plastic for food” »

This video explores what life would be like if we became a Type 3 Civilization. Watch this next video about us becoming a Type 2 civilization: • What If We Became A Type 2 Civilizati…
🎁 5 Free ChatGPT Prompts To Become a Superhuman: https://www.futurebusinesstech.com/su…
🤖 AI for Business Leaders (Udacity Program): https://bit.ly/3Qjxkmu.
☕ My Patreon: / futurebusinesstech.
➡️ Official Discord Server: / discord.

SOURCES:
• https://www.futuretimeline.net.
• The Singularity Is Near: When Humans Transcend Biology (Ray Kurzweil): https://amzn.to/3ftOhXI
• The Future of Humanity (Michio Kaku): https://amzn.to/3Gz8ffA

Continue reading “What If We Became A Type 3 Civilization? 15 Predictions” »

A research team led by the University of California, Irvine has engineered an efficient new enzyme that can produce a synthetic genetic material called threose nucleic acid. The ability to synthesize artificial chains of TNA, which is inherently more stable than DNA, advances the discovery of potentially more powerful, precise therapeutic options to treat cancer and autoimmune, metabolic and infectious diseases.

Bioengineered breast reconstruction and augmentation — dr. luba perry, phd — CEO, reconstruct bio.

Dr. Luba Perry, Ph.D. is Co-Founder and CEO of ReConstruct Bio (https://wyss.harvard.edu/technology/r…), an innovative venture emerging from Harvard’s Wyss Institute (https://wyss.harvard.edu/team/advance…), aimed at redefining the fields of medical reconstruction and aesthetics with an initial application of their groundbreaking technology on breast reconstruction and augmentation. With a multidisciplinary team of experts, the ReConstruct Bio team has developed the BioImplant—a living, bioengineered tissue created from the patient’s own cells, to provide safer, more natural alternative to current standards, which are often associated with significant drawbacks and health concerns.

Continue reading “Dr. Luba Perry, Ph.D. — CEO, ReConstruct Bio — Bioengineered Breast Reconstruction And Augmentation” »

Spider silk is one of the strongest materials on Earth, technically stronger than steel for a material of its size. However, it’s tough to obtain—spiders are too territorial (and cannibalistic) to breed them like silkworms, leading scientists to turn to artificial options.

Teaching microbes to produce the spider silk proteins through genetic engineering is one such option, but this has proved challenging because the proteins tend to stick together, reducing the silk’s yield. So, Bingbing Gao and colleagues wanted to modify the natural protein sequence to design an easily spinnable, yet still stable, spider silk using microbes.

The team first used these microbes to produce the silk proteins, adding extra peptides as well. The new peptides, following a pattern found in the protein sequence of amyloid polypeptides, helped the artificial silk proteins form an orderly structure when folded and prevented them from sticking together in solution, increasing their yield.

Researchers have discovered an antibody able to neutralize all known variants of SARS-CoV-2, the virus that causes COVID-19, as well as distantly related SARS-like coronaviruses that infect other animals.

As part of a new study on hybrid immunity to the virus, the large, multi-institution research team led by The University of Texas at Austin discovered and isolated a broadly neutralizing plasma antibody, called SC27, from a single patient. Using technology developed over several years of research into antibody response, the team led by UT engineers and scientists obtained the exact molecular sequence of the antibody, opening the possibility of manufacturing it on a larger scale for future treatments.

“The discovery of SC27, and other antibodies like it in the future, will help us better protect the population against current and future COVID variants,” said Jason Lavinder, a research assistant professor in the Cockrell School of Engineering’s McKetta Department of Chemical Engineering and one of the leaders of the new research, which was recently published in Cell Reports Medicine.

In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the development of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) systems. In 2020, the Nobel Prize in Chemistry was awarded to the scientists for the discovery of CRISPR–Cas9 system, a revolutionary genome editing technology that advanced DNA therapeutics. Subsequently, the CRISPR–Cas13 system has emerged as a potential tool to identify and rectify errors in RNA sequences. CRISPR–Cas13 is a novel technology is specifically engineered for virus detection and RNA-targeted therapeutics. The CRISPR RNA (CrRNA) targets specific and non-specific RNA sequences, and Cas13 is an effector protein that undergoes conformational changes and cleaves the target RNA. This RNA-targeting system holds tremendous promise for therapeutics and presents a revolutionary tool in the landscape of molecular biology.

Now, in a recently published BioDesign Research study, a team of researchers led by Professor Yuan Yao from ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, China has elucidated the latest research trends of CRISPR–Cas13 in RNA-targeted therapies. Talking about this paper, which was published online on 6 September 2024, in Volume 6 of the journal, Prof. Yao says, “By focusing on RNA-;the intermediary between DNA and proteins-;CRISPR-Cas13 allows scientists to temporarily manipulate gene expression without inducing permanent changes to the genome. This flexibility makes it a safer option in scenarios where genome stability is critical.”

RNA plays a central role in carrying genetic information from DNA to protein-synthesizing machinery, and also regulates gene expression and participates in numerous cellular processes. Defects in RNA splicing or mutations can lead to a wide variety of diseases, ranging from metabolic disorders to cancer. A point mutation occurs when a single nucleotide is erroneously inserted, deleted, or changed. CRISPR–Cas13 plays a role in identifying and correcting these mutations by employing REPAIR (RNA editing for programmable A-to-I replacement) and RESCUE (RNA editing for specific C-to-U exchange) mechanisms. Explaining the applications of Cas13-based gene editors, Prof. Yao adds, “The mxABE editor, for example, can be used to correct a nonsense mutation linked with Duchenne muscular dystrophy that can be corrected with mxABE. This approach has proved high editing efficiency, restoring dystrophin expression to levels more than 50% of those of the wild type.”